EMA Application withdrawn: Susvimo (ranibizumab) — Roche Registration GmbH

View source ↗

Summary

The EMA indicates Susvimo (ranibizumab) application withdrawn by Roche Registration GmbH in the wet age-related macular degeneration program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• SUSVIMO (Ranibizumab)

Snippet

Status: Application withdrawn. Therapeutic area: Wet Macular Degeneration. MAH: Roche Registration GmbH